On May 18, the official WeChat account “Huashan Infection” of Huashan Hospital affiliated to Fudan University announced the first clinical research results of Junshi Bio’s anti-new crown oral drug VV116 in China.
The study involved 136 Omicron patients with COVID-19. Among them, 60 patients took VV116 within 5 days of their first positive nucleic acid test, and 76 patients received standard treatment only without VV116.
The results showed: The average time of nucleic acid conversion of patients who received VV116 orally was 8.56 days, which was less than 11.13 days of the control group.
In the patient group taking VV116, a total of 9 adverse events were reported, of which 7 were mild liver function abnormalities, which recovered spontaneously. There were no serious adverse events.
However, the trial was an open-label, prospective cohort study, and none of the included subjects developed severe or critical illness, To evaluate the efficacy of VV116 in the treatment of severe Omicron infection. The specific research results were published in the journal Emerging Microbes & Infections.
The competition for domestically produced new crown oral drugs has not stopped. Previously at the China Medical Development Conference, Jiang Jiandong, a member of the Chinese Academy of Medical Sciences and academician of the Chinese Academy of Engineering, reported the clinical research results of real biological azvudine: oral administration turned negative within 3-4 days, and the average medication time was 6-7 days. , an average of 9 days of discharge, and the treatment effect was similar for severe and mild patients.
